Orally disintegrating tablets containing bilastine

A formulation of bilastine with D-mannitol, hydroxypropyl cellulose, and crospovidone addresses the issues of hardness and disintegration in orally disintegrating tablets, ensuring rapid disintegration and stability under high humidity, facilitating easy production.

JP7590950B2Active Publication Date: 2024-11-27TAIHO PHARMA CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2021204817
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-12-18
Filing Date
2021-12-17
Publication Date
2024-11-27
Estimated Expiration
2041-12-17

AI Technical Summary

Technical Problem

Existing orally disintegrating tablets face challenges in maintaining high hardness and rapid disintegration under high humidity conditions, and there is a lack of effective methods for ensuring storage stability.

Method used

The formulation includes bilastine, D-mannitol, low-substituted hydroxypropyl cellulose, polyvinyl alcohol, and crospovidone, with specific ratios to achieve tablets that are both hard and disintegrate rapidly, using a simple manufacturing process.

Benefits of technology

The tablets exhibit high hardness, rapid disintegration, and good storage stability, making them suitable for practical use even under high humidity conditions, and are easily manufactured without specialized equipment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590950000007
    Figure 0007590950000007
  • Figure 0007590950000008
    Figure 0007590950000008
  • Figure 0007590950000009
    Figure 0007590950000009
Patent Text Reader

Abstract

To provide an orally disintegrating tablet of bilastine having high tablet hardness, fast disintegrating properties, and high storage stability, and a method for producing the same.SOLUTION: An orally disintegrating tablet contains (1) 2-[4-(2-{4-[1-(2-ethoxy ethyl)-1H-benzimidazole-2-yl]piperidine-1-yl}ethyl)phenyl]-2-methylpropanoic acid or a salt thereof; (2) granules composed of D-mannitol, low-degree-substitution hydroxypropyl cellulose and polyvinyl alcohol (completely saponified material); and (3) a disintegrator.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an orally disintegrating tablet having high tablet hardness, rapid disintegration property and good storage stability, and The present invention relates to a method for producing the same. [Background technology]

[0002] 2-[4-(2-{4-[1-(2-ethoxyethyl) 1H-benzimidazol-2-yl]piperidin-1-yl}ethyl phenyl]-2-methylpropanoic acid (hereinafter referred to as "bilastine" and "compound 1") have been reported (Patent Documents 1 and 2).

[0003] In today's society, where the population is aging, many people take many medications on a daily basis due to the occurrence of various diseases. As the number of elderly people who have no choice but to take medicine increases, the decline in swallowing function associated with aging is causing The number of patients who have difficulty in taking medication is also increasing. For such patients with impaired swallowing function, it is recommended to use oral contraceptives rather than tablets or capsules. Granules such as white granules or fine granules, or those that disintegrate quickly in the mouth with a small amount of water or saliva Orally disintegrating tablets are preferred. Orally disintegrating tablets have both rapid disintegration and high hardness. In addition, it is desirable for the material to have a suitable hardness and sufficient disintegration properties to withstand practical use even under high humidity conditions. Therefore, the manufacturing process for orally disintegrating tablets can be complicated. As a means for overcoming these problems, various methods have been developed.

[0004] For example, Patent Document 3 discloses a method for tableting a disintegrating particle composition by mixing it with a medicamentously active substance. The orally disintegrating tablet has high disintegrability and is easy to manufacture, with cracking and chipping of the tablet reduced to a practical level. It has been shown that the disintegrating particle composition and the pharmaceutical active ingredient can be absorbed into the feces. When mixing and compressing the medicament, the disintegration property and hardness of the resulting orally disintegrating tablet depend on the composition of the medicament. It is thought that the amount varies depending on the combined amount, but no research has been done on the optimal amount. In addition, orally disintegrating tablets generally may lose hardness or experience delayed disintegration under high humidity conditions. However, there is no mention of storage stability.

[0005] Patent Document 4 describes a method for producing a pharmaceutical composition comprising a pharmaceutical ingredient selected from the group consisting of a powder containing a pharmaceutical ingredient and a granule containing a pharmaceutical ingredient. An orally disintegrating tablet is disclosed that includes an ingredient-containing composition, rapidly disintegrating granules, and a lubricant. By incorporating rapid disintegrating granules, it has rapid disintegration and high hardness in the oral cavity. However, Patent Document 4 also shows that tablets can be obtained under high humidity conditions. There is no mention of storage stability.

[0006] From the above, it was found that the material has rapid disintegration and high hardness, and is suitable for practical use even under high humidity conditions. There is still room for improvement in obtaining orally disintegrating tablets that maintain hardness and sufficient disintegrability using a simple method. be.

[0007] As for the dosage form of Compound 1 or its salt, in addition to tablets, other dosage forms have been reported ( However, the composition disclosed in this specification provides rapid disintegration and high hardness. No formulations with this capability have been reported. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] Japanese Patent Application Publication No. 10-059961 [Patent Document 2] Special Publication No. 2005-529120 [Patent Document 3] JP 2017-226600 A [Patent Document 4] International Publication No. WO2017 / 217494 [Patent Document 5] No. CN104398481 [Patent Document 6] No. CN104398512 Summary of the Invention [Problem to be solved by the invention]

[0009] The object of the present invention is to develop a food product that has rapid disintegration properties in the oral cavity, is not damaged during distribution, and To have a suitable hardness for practical use even under high humidity conditions, and to cause a delay in disintegration time The present invention aims to provide an orally disintegrating tablet of Compound 1 or a salt thereof free of the above-mentioned problems, and a method for producing the same. [Means for solving the problem]

[0010] As a result of intensive research to solve the above problems, the present inventors have discovered that bilastine (compound 1); Additives (D-mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol) granules consisting of crospovidone (fully saponified product); Despite its simple manufacturing process, it has a high tablet hardness, rapid disintegration and good storage stability. It has been found that an orally disintegrating tablet containing staphylococcus aureus can be obtained.

[0011] That is, the present invention relates to the following [1] to

[18] . [1](1)2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-benzimi dazol-2-yl]piperidin-1-yl}ethyl)phenyl]-2-methylpropane An acid or its salt, (2) D-mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol Granules made of ethanol (fully saponified product), and (3) Disintegrant An orally disintegrating tablet comprising: [2] The orally disintegrating tablet according to [1], wherein the disintegrant is crospovidone. [3] The total amount of the orally disintegrating tablet is 100.0% by mass, (1) 2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-benzimidazo (phenyl-2-yl)piperidin-1-yl}ethyl)phenyl]-2-methylpropanoic acid or The orally disintegrating tablet according to [1] or [2], containing 5.0 to 23.0% by mass of the salt. [4] The total amount of the orally disintegrating tablet is 100.0% by mass, (3) The oral preparation according to [2] or [3], containing 1.0 to 10.0% by mass of crospovidone. Intracavitary disintegrating tablets. [5] The total amount of the orally disintegrating tablet is 100.0% by mass. (3) A composition according to any one of [2] to [4], which contains 1.0 to 5.0% by mass of crospovidone. Orally disintegrating tablets. [6] The total amount of the orally disintegrating tablet is 100.0% by mass. (3) The oral cavity preparation according to any one of [2] to [5], which contains 3.0% by mass of crospovidone. Internally disintegrating tablets. [7] The total amount of the orally disintegrating tablet is 100.0% by mass. (2) D-mannitol 90.0 to 95.0% by mass, low-substituted hydroxypropylcellulose 5.0-7.0% by mass of rosin, 0.10-0.0% by mass of polyvinyl alcohol (fully saponified) Any of [1] to [6] containing 72.0 to 88.0 mass% of granulated material having a mass ratio of 0.30 mass%. An orally disintegrating tablet as described above. [8] The total amount of the orally disintegrating tablet is 100.0% by mass. (2) 64.0 to 84.0% by mass of D-mannitol and low-substituted hydroxypropylcellulose 3.0-6.2% by mass of rosacea, 0.07-0.05% by mass of polyvinyl alcohol (fully saponified) An orally disintegrating tablet according to any one of [1] to [7], containing 0.30% by mass. [9] The orally disintegrating tablet according to any one of [1] to [8], having a tablet hardness of 60 N or more.

[10] The orally disintegrating tablet according to any one of [1] to [9], which has a disintegration time of 30 seconds or less. .

[11] The oral disintegrating agent according to any one of [1] to

[10] , having a disintegration time of 25 seconds or less. Tablet.

[0012]

[12] (1)2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-benzyl Midazol-2-yl]piperidin-1-yl}ethyl)phenyl]-2-methylpropane acid or its salts, (2) D-mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol Granules made of ethanol (fully saponified product), and (3) Crospovidone A method for producing an orally disintegrating tablet, comprising the steps of: mixing the components (1) to (3); and compressing the mixture into tablets. [12-1] A method for producing an orally disintegrating tablet, comprising the steps of: A step of mixing the following components (1) to (3): (1) 2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-benzimidazo phenyl-2-yl]piperidin-1-yl}ethyl)phenyl]-2-methylpropanoic acid or is its salt, (2) D-mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol Granules made of coal (fully saponified), and (3) crospovidone; and Compressing the resulting mixture into tablets. The method comprising:

[0013]

[13] (1)2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-benzyl Midazol-2-yl]piperidin-1-yl}ethyl)phenyl]-2-methylpropane acid or its salts, (2) D-mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol Granules made of ethanol (fully saponified product), and (3) Crospovidone A pharmaceutical composition which is an orally disintegrating tablet comprising:

[14] The pharmaceutical composition described in

[13] for treating an allergic disease or its symptoms.

[15] The orally disintegrating tablet according to any one of [1] to

[11] for use as a medicine. .

[16] Any of [1] to

[11] for use in treating an allergic disease or its symptoms. An orally disintegrating tablet as described in any one of the above.

[17] Orally administering to a subject the orally disintegrating tablet according to any one of [1] to

[11] Included are methods of treating a subject.

[18] Orally administering to a subject the orally disintegrating tablet according to any one of [1] to

[11] 23. A method of treating an allergic disease or a symptom thereof in a subject, comprising administering to said subject Effect of the Invention

[0014] According to the present invention, there are provided an orally disintegrating tablet of bilastine and a method for producing the same. The orally disintegrating tablets have rapid disintegration and high hardness, and are hard enough to withstand practical use even under high humidity conditions. The oral composition of the present invention also has good storage stability because it maintains a sufficient degree of viscosity and disintegrability. Intracavitary disintegrating tablets can be easily produced by conventional pharmaceutical manufacturing processes without requiring special manufacturing equipment. It is possible. [Brief description of the drawings]

[0015] [Figure 1] FIG. 1 is a graph showing the results of measuring the hardness (N) of tablets produced in Examples 2 to 6 and Comparative Example 4 immediately after tableting (initial) and after leaving the tablets unpackaged under conditions of 40°C and 75% relative humidity for 1 day (40°C / 75%RH (open) 1 day). [Diagram 2] FIG. 1 is a graph showing the results of measuring the disintegration time of tablets produced in Examples 2 to 6 and Comparative Example 4 immediately after tableting (initial) and after leaving them unpackaged under 40°C and 75% relative humidity conditions for 1 day (40°C / 75%RH (open) 1 day). [Diagram 3] 1 is a photograph showing the appearance of tablets produced in Examples 2 to 6 and Comparative Example 4 after being left unpackaged under conditions of 40° C. and 75% relative humidity for 1 day (40° C. / 75% RH (open) 1 day). [Figure 4] FIG. 1 is a graph showing the results of measuring the hardness (N) of the tablets produced in Examples 7 to 9 immediately after tableting (initial) and after leaving them unpackaged under 40°C and 75% relative humidity conditions for 1 day (40°C / 75%RH (open) 1 day). [Diagram 5] FIG. 1 is a graph showing the results of measuring the disintegration time of tablets produced in Examples 7 to 9 immediately after tableting (initial) and after leaving them unpackaged under 40°C and 75% relative humidity conditions for 1 day (40°C / 75%RH (open) 1 day). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] This application claims priority to Japanese Patent Application No. 2020-209788, filed on December 18, 2020, the entire contents of which are incorporated herein by reference. The orally disintegrating tablet and its manufacturing method according to the present invention will be described below. However, the orally disintegrating tablet and its manufacturing method according to the present invention should not be construed as being limited to the description of the following embodiments and examples.

[0017] In the present invention, the orally disintegrating tablet refers to a tablet that can be taken by disintegrating in the oral cavity without water or with a small amount of water. Preferably, the tablet is capable of being absorbed by saliva alone in the oral cavity without the intake of water. It is a tablet that can be taken by disintegrating in the oral cavity. The dosage form of the orally disintegrating tablet is not particularly limited. However, there are various forms, such as plain tablets, chewable tablets, and film-coated tablets. There are no particular limitations on the shape, and the shape may be disk-like, doughnut-like, spherical, elliptical, or the like.

[0018] In the present invention, the active ingredient of the orally disintegrating tablet is 2-[4-(2-{4-[1-(2-ene (1H-benzimidazol-2-yl)piperidin-1-yl}ethyl )phenyl]-2-methylpropanoic acid ("Compound 1" or "Bilastine") or its It is a salt and is represented by the following structural formula (I).

[0019] [ka]

[0020] Compound 1 or a salt thereof is a known compound, and is described, for example, in Patent Document 1 (JP-A-10-05535). The compound can be synthesized according to the method described in US Pat. No. 5,9961.

[0021] Compound 1 or a salt thereof may be a solvate (e.g., a hydrate, etc.) or a non-solvate. In the present invention, both are encompassed in "Compound 1 or a salt thereof."

[0022] In the present invention, the salt of Compound 1 means a pharma- ceutically acceptable salt.

[0023] A pharma- ceutically acceptable salt is a salt that possesses the desired pharmacological activity of a compound, and is inorganic or Prepared from pharma- ceutically acceptable non-toxic bases or acids, including organic bases and inorganic or organic acids. It means salt that can be used.

[0024] Pharmaceutically acceptable salts of Compound 1 include, but are not limited to, hydrochloride, Addition salts with inorganic acids such as sulfuric acid, acetic acid, citric acid, tartaric acid, maleic acid, and other organic acids; Salts with alkaline metals such as calcium and sodium, and alkaline earth metals such as calcium and magnesium Examples of the salts include salts with organic bases such as metal salts, ammonium salts, ethylamine salts, and arginine salts. can be done.

[0025] The orally disintegrating tablet containing compound 1 or a salt thereof in the present invention comprises compound 1 or a salt thereof, D-mannitol, low-substituted hydroxypropyl cellulose, polyvinyl alcohol (complete Contains fully saponified matter) and disintegrant.

[0026] In a preferred embodiment of the present invention, the orally disintegrating tablet containing Compound 1 or a salt thereof is Compound 1 or a salt thereof; D-mannitol, low-substituted hydroxypropyl cellulose and poly Granules made of vinyl alcohol (completely saponified); and containing crospovidone .

[0027] In the present invention, the content of Compound 1 in the orally disintegrating tablet containing Compound 1 or a salt thereof is The dosage is 1 to 90 mg / tablet, preferably 3 to 60 mg / tablet, and more preferably 9 to 50 mg. , for example, 10 mg / tablet, 20 mg / tablet or 40 mg / tablet.

[0028] The content of Compound 1 or a salt thereof used in the present invention is determined based on dissolution, stability, absorbability, and production efficiency. From the standpoint of manufacturability, etc., the total amount of the orally disintegrating tablet is 100.0% by mass, and the mass is set to 1.0 to 50.0% by mass. % by mass, more preferably 2.0 to 30.0% by mass, and even more preferably Preferably, it is 5.0 to 23.0 mass%, and even more preferably, it is 6.0 to 22.0 mass%. and most preferably 10.0 to 12.0 mass %.

[0029] The orally disintegrating tablet containing Compound 1 or a salt thereof of the present invention contains D-manganese as an additive. Granulated material consisting of nitrile, low-substituted hydroxypropyl cellulose, and polyvinyl alcohol The orally disintegrating tablet according to the present invention contains various additives other than those mentioned above. Examples of additives include excipients, disintegrants, binders, colorants, flavoring agents, and flavor masking agents. Examples of suitable additives include food additives, sweeteners, lubricants, flow agents, and coating agents.

[0030] In the present invention, the excipient is water-soluble or water-compatible in consideration of the mouthfeel, etc. Preferred are mannitol, erythritol, sorbitol and xylitol. Which sugar alcohols, trehalose, cyclodextrin, corn starch, sucrose , crystalline cellulose, anhydrous calcium hydrogen phosphate, calcium carbonate, etc., either alone or in combination. In the present invention, sugar alcohols are preferred, and more preferred are More preferably, mannitol is used, and particularly preferably D-mannitol.

[0031] The content of D-mannitol was 10 As 0.0 mass%, 64.0 to 84.0 mass% is preferable, and 64.8 to 83.6 mass% is preferable. More preferably, 68.0 to 81.0% by mass, and more preferably, 68.4 to 80.8% by mass. is more preferable, and 74.7 to 78.9 mass % is particularly preferable.

[0032] In the present invention, the disintegrant is, for example, low-substituted hydroxypropyl cellulose, crosslinker, etc. Povidone, carmellose calcium, carmellose sodium, croscarmellose sodium The disintegrants can be selected from sodium, carmellose, various starches, etc. In the present invention, the low-substituted hydroxypropyl esters can be used alone or in combination. Preferred are ropyl cellulose and crospovidone.

[0033] The content of low-substituted hydroxypropyl cellulose was determined by the oral administration of Compound 1 or a salt thereof. The amount is preferably 3.0 to 6.2% by mass, and more preferably 3.6 to 6.2% by mass, based on 100.0% by mass of the total amount of the intraluminal disintegrating tablet. 6.2% by mass is more preferable, 3.8 to 6.0% by mass is more preferable, and 4.2 to 5.8% by mass is more preferable. % by volume is particularly preferred.

[0034] The content of crospovidone was determined by dividing the total amount of the orally disintegrating tablet containing Compound 1 or a salt thereof by 100. As for .0 mass%, 1.0 to 10.0 mass% is preferable, and 1.0 to 5.0 mass% is more preferable. Preferably, the content is 1.0 to 4.0 mass %, more preferably, 1.0 to 3.0 mass %. , 3.0 mass % is particularly preferred.

[0035] In the present invention, the binder is, for example, hydroxypropyl cellulose, hydroxypropyl Pyrmethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol (fully saponified) The excipient may be selected from the group consisting of macrogol, and the compounds listed above as excipients. These binders can be used alone or in appropriate combination. Vinyl alcohol (fully saponified) is preferred.

[0036] In the present invention, the polyvinyl alcohol is not limited to polyvinyl alcohol. Although polyvinyl alcohol (completely saponified) may be used, polyvinyl alcohol (completely saponified) is preferable. be.

[0037] The content of polyvinyl alcohol (completely saponified) is The total amount of the intracavitary disintegrating tablet is taken as 100.0% by mass, and the amount is preferably 0.07 to 0.30% by mass, and 0. 0.07 to 0.26 mass% is more preferable, 0.08 to 0.26 mass% is even more preferable, and 0.07 to 0.26 mass% is even more preferable. An amount of 0.08 to 0.25 mass % is particularly preferred.

[0038] In the present invention, the lubricant is, for example, magnesium stearate, stearic acid, stearyl stearate, etc. Calcium phosphate, light anhydrous silicic acid, sodium stearyl fumarate, talc, hydrogenated Vegetable oil, microcrystalline wax, sucrose fatty acid ester, polyethylene glycol These lubricants may be used alone or in appropriate combination. In the present invention, magnesium stearate is preferred.

[0039] The content of magnesium stearate in all orally disintegrating tablets containing Compound 1 or a salt thereof is The amount is preferably 0.5 to 1.5% by mass, and particularly preferably 1.0% by mass, based on 100.0% by mass. I wish.

[0040] In the orally disintegrating tablet containing Compound 1 or a salt thereof of the present invention, the flavoring agent is, for example, For example, aspartame, saccharin, sodium saccharin, dipotassium glycyrrhizinate , stevia, thaumatin, sucralose, acesulfame K, l-menthol, camphor These flavoring agents may be used alone or in combination. In the present invention, aspartame and sucralose are preferred. Spartame is even more preferred.

[0041] The content of the flavoring agent is 100.0 mass of the orally disintegrating tablet containing Compound 1 or a salt thereof. %, preferably 0.1 to 5.0 mass%, more preferably 1.0 to 5.0 mass%, 0.0 mass % is even more preferred.

[0042] In the present invention, examples of the fluidizing agent include silicon dioxide, sodium silicate, talc, stearyl alcohol, and the like. magnesium allanate.

[0043] In the present invention, the coloring agent may be food yellow No. 5, food blue No. 2, food lake Examples of the pigments include iron oxide, yellow iron oxide, and titanium oxide.

[0044] In the present invention, the coating agent is hydroxypropyl methylcellulose (hydroxypropyl methylcellulose). Promellose, TC-5, METOLOSE (registered trademark, etc.) and polyethylene glycol PEG400, PEG1500, PEG4000, PEG6000, macrogol 400, Macrogol 1500, Macrogol 4000, Macrogol 6000, etc.) Some examples include:

[0045] The orally disintegrating tablet of the present invention is made of orange, Various flavorings such as lemon, lime, etc. can be used as flavoring agents.

[0046] In a preferred embodiment, the orally disintegrating tablet contains D-macrobiotics, with the total amount being 100.0% by mass. 64.0 to 84.0 mass% of ethanol, 3. 0 to 6.2% by mass, polyvinyl alcohol (fully saponified) 0.07 to 0.30% by mass Contains.

[0047] In the present invention, other additives such as sweeteners, flavorings, and antistatic agents may be used. , surfactants, wetting agents, fillers, bulking agents, adsorbents, moisture-proofing agents, antioxidants, preservatives (e.g. Preservatives, buffers, etc. may also be used.

[0048] In preparing the orally disintegrating tablet of the present invention, excipients, disintegrants, binders, etc. are mixed in advance. Premixes containing the additives mentioned above can be used. For example, SmartEx® D-mannitol, low-substituted hydroxypropyl cellulose, polyvinyl alcohol ( In the present invention, the excipient, disintegrant, binder When using premixed additives, the amount of additive to be added should be determined taking into consideration the composition and physical properties of the additive. In order to adjust the moldability and disintegration properties of the orally disintegrating tablet, Co-formulants and disintegrants may be added.

[0049] D-mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol The granules (completely saponified product) are composed of 90.0 to 95.0% by mass of D-mannitol, Low-substituted hydroxypropyl cellulose at 5.0 to 7.0% by mass, polyvinyl alcohol (completely saponified product) at 0.10 to 0.30% by mass. For example, SmartE x (registered trademark), SmartEx (registered trademark), QD-50 and QD-100 is commercially available.

[0050] D-mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol The content of the granules consisting of (completely saponified product) is With the total weight of the tablet being 100.0% by mass, 70.0 to 90.0% by mass is more preferable, and 72.0 Up to 88.0% by mass is more preferable, 76.0 to 85.0% by mass is even more preferable, and 83. 0% by mass is particularly preferred.

[0051] These additives are not subject to any particular restrictions as long as their quality is guaranteed for use in pharmaceutical formulations. These additives may be used alone or in combination. For details of these additives, see, for example, Pharmaceutical Excipients Standards 20. This can be confirmed by 18.

[0052] The orally disintegrating tablet of the present invention can be produced by a known method for producing a formulation. For example, , a method in which the ingredients are mixed and then compressed into tablets, a method in which the ingredients are mixed and granulated and then compressed into tablets, It is possible to use a method in which the ingredients are granulated, mixed with other ingredients, and then compressed into tablets. For example, the granulation method includes fluidized bed granulation, stirring granulation, rolling fluidized bed granulation, extrusion granulation, Granulation can be produced by spray drying granulation method, dry granulation method, etc. The granulated product may be dried. The tableting is performed using a known tableting machine until the resulting tablets have an appropriate size. The tablet is adjusted to have a hardness and to be rapidly disintegrated as an orally disintegrating tablet. As the tablet press, for example, a rotary tablet press, a single shot tablet press, a hydraulic press, etc. may be appropriately selected and used. The tableting pressure can be adjusted depending on the tableting method, tablet press used, tablet size and thickness, The dosage is adjusted appropriately depending on the type of active ingredient, etc.

[0053] Therefore, the method for producing an orally disintegrating tablet according to the present invention comprises the steps of: The manufacturing method according to the present invention includes a step of mixing the ingredients and a step of compressing the mixture into tablets. may further include a step of granulating the whole, a step of coating the tablets, etc.

[0054] The stability in the present invention refers to the physical stability of the formulation and the stability of the compound which is the active ingredient. The improvement of stability includes both the chemical stability of 1 or its salts. To compare the state of the formulation before and after the drug product under the same conditions, and to quickly check the chemical purity of Compound 1 or its salt. This can be judged by comparing with liquid chromatography. Considering the storage and distribution of orally disintegrating tablets or pharmaceutical compositions, This is the issue.

[0055] The hardness in the present invention is a standard known in the field of tablets, and is described in, for example, the following test example. Specifically, the tablet hardness is measured using a tablet hardness tester (e.g., PC-30, manufactured by Okada Seiko Co., Ltd.). The tablet was clamped from the side with the tool and gradually pressurized to break the tablet. This refers to the load (N) at the time when

[0056] From the practical standpoint of manufacturing, transportation, and clinical use, tablet hardness should be relatively high. The tablet hardness of the orally disintegrating tablet of the present invention is preferably about 60 N or more. More preferably, the hardness is about 70N or more, and even more preferably, the hardness is 80N or more. Although there is no particular limitation, it is generally 200N or less.

[0057] The disintegration time in the present invention is the time measured by the disintegration test method specified in the Japanese Pharmacopoeia. The time is measured by the method described in the following Test Example 2. was measured using a disintegration tester (NT-4H, NT-4H(P), manufactured by Toyama Sangyo Co., Ltd.). Ta.

[0058] In the orally disintegrating tablet of the present invention, the disintegration time is preferably 30 seconds or less, more preferably Or less than 25 seconds.

[0059] In the present invention, the oral disintegration time is the time required for a tablet to be disintegrated in a manner that mimics the disintegration behavior in the oral cavity. The disintegration time is measured by, for example, the method described in Test Example 1 below. In the present invention, an orally disintegrating tablet tester (ODT-101, manufactured by Toyama Sangyo Co., Ltd.) was used. ) was used for the measurements.

[0060] The orally disintegrating tablet of the present invention preferably has an oral disintegration time of 30 seconds or less. More preferably, it is 25 seconds or less.

[0061] The orally disintegrating tablet of the present invention has both a certain level of tablet hardness and a rapid oral disintegration time. For example, it is desirable that the tablet has a tablet hardness of about 60 N or more and is disintegratable in the oral cavity. The break time is less than 30 seconds.

[0062] Tablet friability is a well-known standard in the tablet field and is described in the Japanese Pharmacopoeia, Tablet Friability Test Method. Accordingly, a test was conducted.

[0063] Compound 1 or its salt is manufactured and sold in various countries around the world as a therapeutic agent for allergic diseases. Therefore, the orally disintegrating tablet according to the present invention can be used as a pharmaceutical composition, for example, for allergy prevention. The composition can be used as a pharmaceutical composition for treating a chronic disease or its symptoms. The orally disintegrating tablet according to the present invention is effective in treating allergic rhinitis (hay fever), urticaria, skin diseases ( It can be used as a therapeutic agent for itching associated with eczema, dermatitis, and cutaneous pruritus.

[0064] When used as a pharmaceutical composition for treating a subject, the orally disintegrating tablet of the present invention is The dosage is determined according to the age, weight, condition, etc. of the subject, the purpose of treatment (e.g., disease, These will vary depending on the type of treatment or prevention of symptoms, etc., and a person skilled in the art can set them appropriately. For example, the amount of Compound 1 can be converted to 10 to 40 mg per day, preferably Administer 20 mg or less.

[0065] The present invention will now be described in detail with reference to examples, but the present invention is not limited to these examples. stomach. EXAMPLES

[0066] [Example 1: Production of tablet A] Bilastine (SAI LIFE SCIENCES LIMITED) 2g; D-Ma butyl ether, low-substituted hydroxypropyl cellulose and polyvinyl alcohol (completely Granules made of nitrile (SmartEx (registered trademark) QD-50; Shin-Etsu Chemical Co., Ltd.) (D-mannitol 90.0-95.0%, low-substituted hydroxypropyl Pillcellulose 5.0-7.0%, polyvinyl alcohol (fully saponified) 0.1-0. 3%), flavoring agent 0.1g, magnesium stearate (vegetable, Taihei Chemical Industry Co., Ltd. Mix 0.15g of the drug (manufactured by the company) thoroughly and add 150mg of bilastine per tablet (20mg). The tablets were compressed with a hydraulic press (manufactured by Riken Seiki Co., Ltd.) at a compression force of 500 kgf to obtain tablets with a diameter of 8 mm and Tablet A with a mass of 150 mg was obtained.

[0067] [Comparative Example 1: Production of tablet a] Bilastine (SAI LIFE SCIENCES LIMITED) 2g; D-Ma A mixture of granitol, carmellose, microcrystalline cellulose and crospovidone (granules) Filler D (registered trademark): Daicel Corporation) 12.75 g (D-mannitol 53.0 to 59.0%, carmellose 15.0-25.0%, crystalline cellulose 17.0-23. 0%, crospovidone 3.4-4.6%, flavoring agent 0.1g, magnesium stearate Mix thoroughly 0.15g of sodium (plant-based, manufactured by Taihei Chemical Industry Co., Ltd.) and add 0.15g of sodium per tablet. 150 mg and 20 mg of bilastine were compressed at a compression force of 5 using a hydraulic press (manufactured by Riken Seiki Co., Ltd.). The mixture was compressed at 00 kgf to obtain tablet a having a diameter of 8 mm and a mass of 150 mg.

[0068] [Comparative Example 2: Production of tablet b] Bilastine (SAI LIFE SCIENCES LIMITED) 2g; D-Ma Granules consisting of cornstarch and cornstarch (PEARLITOL®) Flash; ROQUETTE) 12.75g (D-mannitol 78.0-82 0.0%, corn starch 15.0-19.0%), flavoring agent 0.1g, ste Add 0.15 g of magnesium phosphate (vegetable-based, manufactured by Taihei Chemical Industry Co., Ltd.) and mix thoroughly. Each tablet weighs 150 mg and contains 20 mg of bilastine. The tablets are press-pressed using a hydraulic press (manufactured by Riken Seiki Co., Ltd.). The mixture was compressed with a compression force of 500 kgf to obtain tablet b having a diameter of 8 mm and a mass of 150 mg.

[0069] [Comparative Example 3: Production of tablet c] Bilastine (SAI LIFE SCIENCES LIMITED) 2g; D-Ma Inositol, xylitol, crystalline cellulose, crospovidone and aluminometasilicate 12.75 g of a mixture of magnesium (F-Melt (registered trademark); Fuji Chemical Co., Ltd.) (D -Mannitol 62.3-67.2%, xylitol 4.2-5.8%, crystalline cellulosic acid 13.5-16.5% crospovidone, 6.8-9.2% aluminum metasilicate Contains 5.9-8.0% magnesium stearate), flavoring agent 0.1g, magnesium stearate (Plant-based, manufactured by Taihei Chemical Industry Co., Ltd.) 0.15 g was thoroughly mixed and each tablet weighed 150 g. mg, and 20 mg of bilastine were compressed at a compression force of 500 kPa using a hydraulic press (manufactured by Riken Seiki Co., Ltd.). The mixture was compressed using a gf to obtain tablet C having a diameter of 8 mm and a mass of 150 mg.

[0070] [Test Example 1: Measurement of tablet hardness and disintegration time] The tablets produced in Example 1 and Comparative Examples 1 to 3 were subjected to a tablet hardness test using a tablet hardness tester (PC-30, The hardness in the diameter direction was measured using a hardness gauge manufactured by Okada Seiko Co., Ltd., and the hardness (N) was calculated from the average value of three tablets. The disintegration time was measured using an oral disintegrating tablet tester (ODT-101, manufactured by Toyama Sangyo Co., Ltd.). Test liquid: water (37.0±1℃), weight: 10g, rotation speed: 20rpm The time from when the weight touched the tablet until the tablet completely disintegrated was measured. The results are shown in Table 1. In Table 1, the numerical values ​​of the components are in mass %.

[0071] As is clear from the results in Table 1, the tablet of Example 1 has both high hardness and rapid disintegration. It was confirmed that.

[0072] [Table 1]

[0073] [Example 2: Production of tablet B] Bilastine (SAI LIFE SCIENCES LIMITED) 40g; D- Mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol (complete Granules (SmartEx® QD-50; D-mannitol) 90.0-95.0%, low-substituted hydroxypropyl cellulose 5.0-7.0%, poly Vinyl alcohol (fully saponified) 0.1-0.3% (Shin-Etsu Chemical Co., Ltd.) 304.8 g, Crospovidone (Kollidon® CL-SF, manufactured by BASF) ) 3.6g, Aspartame (Ajinomoto Co., Inc.) 8g, Magnesium Stearate (Plant Mix 3.6g of each tablet (physical properties, manufactured by Taihei Chemical Industry Co., Ltd.) thoroughly to obtain a tablet with a mass of 180 mg. Bilastine 20mg, Crospovidone 1.8mg, rotary tablet press "12TU-AW " (Kikusui Seisakusho Co., Ltd.) was used to compress the tablet at a compression force of 930 kgf, resulting in a diameter of 8 mm and a mass of 1 Tablet B weighing 80 mg was obtained.

[0074] [Example 3: Production of tablet C] Bilastine (SAI LIFE SCIENCES LIMITED) 40g; D- Mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol (complete Granules (SmartEx® QD-50; D-mannitol) 90.0-95.0%, low-substituted hydroxypropyl cellulose 5.0-7.0%, poly Vinyl alcohol (fully saponified) 0.1-0.3% (Shin-Etsu Chemical Co., Ltd.) 297.6 g, crospovidone (Kollidon® CL-SF, manufactured by BASF) ) 10.8g, Aspartame (Ajinomoto Co., Inc.) 8g, Magnesium stearate ( Thoroughly mix 3.6g of vegetable extract (manufactured by Taihei Chemical Industry Co., Ltd.) to give a tablet weighing 180mg. , bilastine 20mg, crospovidone 5.4mg, rotary tablet press "12TU-A The tablets were compressed using a compression force of 920 kgf using a 100% ... Tablet C weighing 180 mg was obtained.

[0075] [Example 4: Production of tablet D] Bilastine (SAI LIFE SCIENCES LIMITED) 40g; D- Mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol (complete Granules (SmartEx® QD-50; D-mannitol) 90.0-95.0%, low-substituted hydroxypropyl cellulose 5.0-7.0%, poly Vinyl alcohol (fully saponified) 0.1-0.3% (Shin-Etsu Chemical Co., Ltd.) 294 g, Crospovidone (Kollidon® CL-SF, manufactured by BASF) 1 4.4g, Aspartame (Ajinomoto Co., Inc.) 8g, Magnesium Stearate (Plant (Taihei Chemical Industry Co., Ltd.) 3.6 g was thoroughly mixed, and each tablet had a mass of 180 mg. Rotary tablet press "12TU-AW" for Rustin 20mg and Crospovidone 7.2mg (manufactured by Kikusui Seisakusho Co., Ltd.) was used to compress the tablets to a diameter of 8 mm and a mass of 18 Tablet D weighing 0 mg was obtained.

[0076] [Example 5: Production of tablet E] Bilastine (SAI LIFE SCIENCES LIMITED) 40g; D- Mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol (complete Granules (SmartEx® QD-50; D-mannitol) 90.0-95.0%, low-substituted hydroxypropyl cellulose 5.0-7.0%, poly Vinyl alcohol (fully saponified) 0.1-0.3% (Shin-Etsu Chemical Co., Ltd.) 290.42 g, Crospovidone (Kollidon® CL-SF, BASF Aspartame (Ajinomoto Co., Inc.) 8g, Magnesium stearate (Plant Mix 3.6g of each tablet (physical properties, manufactured by Taihei Chemical Industry Co., Ltd.) thoroughly to obtain a tablet with a mass of 180 mg. Bilastine 20mg, Crospovidone 9mg, Rotary Tablet Press "12TU-AW" The tablets were compressed with a compression force of 900 kgf using a machine manufactured by Kikusui Seisakusho Co., Ltd., and the diameter was 8 mm and the mass was 180 g. Tablets E weighing 100 mg were obtained.

[0077] [Example 6: Production of tablet F] Bilastine (SAI LIFE SCIENCES LIMITED) 40g; D- Mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol (complete Granules (SmartEx® QD-50; D-mannitol) 90.0-95.0%, low-substituted hydroxypropyl cellulose 5.0-7.0%, poly Vinyl alcohol (fully saponified) 0.1-0.3% (Shin-Etsu Chemical Co., Ltd.) 272.43 g, Crospovidone (Kollidon® CL-SF, BASF Aspartame (Ajinomoto Co., Inc.) 8g, Magnesium stearate (plant) Mix 3.6g of each tablet (physical properties, manufactured by Taihei Chemical Industry Co., Ltd.) thoroughly to obtain a tablet with a mass of 180 mg. Bilastine 20mg, Crospovidone 18mg, Rotary Tablet Press "12TU-AW" (manufactured by Kikusui Seisakusho Co., Ltd.) was used to compress the tablets at a compression force of 820 kgf, resulting in a diameter of 8 mm and a mass of 18 Tablet F weighing 0 mg was obtained.

[0078] Comparative Example 4: Production of Tablet X Bilastine (SAI LIFE SCIENCES LIMITED) 40g; D- Mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol (complete A granulated material consisting of a saponified product (SmartEx® QD-50; Shin-Etsu Chemical Co., Ltd.) Aspartame (manufactured by Ajinomoto Co., Inc.) 308.4g, Magnesium stearate (manufactured by Ajinomoto Co., Inc.) 8g Thoroughly mix 3.6g of sodium (plant-based, manufactured by Taihei Chemical Industry Co., Ltd.) and give a tablet of mass 1 80mg and bilastine 20mg using a rotary tablet press "12TU-AW" (KIKUSUI Co., Ltd.) The tablet was compressed at a compression force of 970 kgf using a tablet press (manufactured by Seisakusho Co., Ltd.) to produce tablet X with a diameter of 8 mm and a mass of 180 mg. obtained.

[0079] The amounts of the components in Examples 2 to 6 and Comparative Example 4 are summarized in Table 2. The values ​​in Table 2 are in mass %.

[0080] [Table 2]

[0081] [Test Example 2: Measurement of tablet hardness and disintegration time] The tablets produced in Examples 2 to 6 and Comparative Example 4 were subjected to a tablet hardness test using a tablet hardness tester (PC-30, The hardness in the diameter direction was measured using a hardness gauge (manufactured by Okada Seiko Co., Ltd.), and the hardness (N) was calculated from the average value of five tablets. The disintegration time was measured using a disintegration tester (NT-4H, NT-4H(P), manufactured by Toyama Sangyo Co., Ltd. ) was used, and the test liquid was water (37±2℃), and the disk was not used. The time it took for the tablet to completely disintegrate was measured. The hardness and disintegration time were measured immediately after tableting (initial ), and after leaving unpackaged at 40℃ and 75% relative humidity for 1 day (40℃ / 75%RH The results are shown in Figures 1 and 2, respectively.

[0082] [Test Example 3] The tablets produced in Examples 2 to 6 and Comparative Example 4 were stored at 40°C and 75% relative humidity without packaging. Check the appearance after leaving it for one day under humid conditions (40℃ / 75%RH (open) 1day) The results are shown in Figure 3.

[0083] [Test Example 4: Measurement of the amount of related substances] The tablets produced in Examples 2 to 6 and Comparative Example 4 were subjected to drying at room temperature or under severe conditions (40°C / 7 After storage at 5% RH (open) for one month, the amount of related substances formed was measured according to the Japanese Pharmacopoeia General Standards. Test method: Measured by liquid chromatography as described in the Physical Test Methods. The results are shown in Table 3. .

[0084] [Test Example 5: Measurement of wear and tear] The tablets produced in Example 6 were subjected to severe conditions (40°C / 75% RH (open)). After storing at room temperature for one day, the tablet friability was measured according to the tablet friability test method prescribed in the Japanese Pharmacopoeia.

[0085] As is clear from the results of Figures 1 and 2, the amount of crospovidone in the range of 1 to 10% by mass This formulation has both high hardness and rapid disintegration properties, and when humidified (40℃ / 75%RH ( It was confirmed that the tablet maintained sufficient hardness and rapid disintegration even after 1 day of storage. The friability of a tablet containing 10% by mass of crospovidone (tablet F) when hydrated was 0.20%. Furthermore, as is clear from the results in Figure 3 and Table 3, there was no change in properties due to moisture absorption or the occurrence of related substances. No significant increase in the amount was observed, confirming good storage stability.

[0086] [Table 3]

[0087] [Example 7: Production of tablet H] Bilastine (SAI LIFE SCIENCES LIMITED) 20g, D- Mannitol, low-substituted hydroxypropyl cellulose, polyvinyl alcohol (completely nitrate) Granulated material (SmartEx (registered trademark) QD-50, Shin-Etsu Chemical Co., Ltd.) 3 17.6 g, Crospovidone (Kollidon® CL-SF, manufactured by BASF) 10.8g, Aspartame (Ajinomoto Co., Inc.) 8g, Magnesium Stearate (Plant Mix 3.6g of each tablet (physical properties, manufactured by Taihei Chemical Industry Co., Ltd.) thoroughly to obtain a tablet with a mass of 180 mg. Bilastine 10mg, rotary tablet press "12TU-AW" (manufactured by Kikusui Seisakusho Co., Ltd.) The mixture was compressed using a compression force of 850 kgf to obtain tablet H having a diameter of 8 mm and a mass of 180 mg.

[0088] [Example 8: Production of tablet I] Bilastine (SAI LIFE SCIENCES LIMITED) 40g, D- Mannitol, low-substituted hydroxypropyl cellulose, polyvinyl alcohol (completely nitrate) Granulated material (SmartEx (registered trademark) QD-50, manufactured by Shin-Etsu Chemical Co., Ltd.) 2 97.6 g, Crospovidone (Kollidon® CL-SF, manufactured by BASF) 10.8g, Aspartame (Ajinomoto Co., Inc.) 8g, Magnesium Stearate (Plant Mix 3.6g of each tablet (physical properties, manufactured by Taihei Chemical Industry Co., Ltd.) thoroughly to obtain a tablet with a mass of 180 mg. Bilastine 20mg, rotary tablet press "12TU-AW" (manufactured by Kikusui Seisakusho Co., Ltd.) The mixture was compressed using a compression force of 920 kgf to obtain tablet I having a diameter of 8 mm and a mass of 180 mg.

[0089] [Example 9: Production of tablet J] Bilastine (SAI LIFE SCIENCES LIMITED) 80g, D- Mannitol, low-substituted hydroxypropyl cellulose, polyvinyl alcohol (completely nitrate) Granulated material (SmartEx (registered trademark) QD-50, manufactured by Shin-Etsu Chemical Co., Ltd.) 2 57.6 g, Crospovidone (Kollidon® CL-SF, manufactured by BASF) 10.8g, Aspartame (Ajinomoto Co., Inc.) 8g, Magnesium Stearate (Plant Mix 3.6g of each tablet (physical properties, manufactured by Taihei Chemical Industry Co., Ltd.) thoroughly to obtain a tablet with a mass of 180 mg. Bilastine 40mg, rotary tablet press "12TU-AW" (manufactured by Kikusui Seisakusho Co., Ltd.) The mixture was compressed using a compression force of 880 kgf to obtain tablet J having a diameter of 8 mm and a mass of 180 mg.

[0090] The amounts of the components in Examples 7 to 9 are summarized in Table 4. The values ​​in Table 4 are in mass %.

[0091] [Table 4]

[0092] The hardness and disintegration time of the tablets were measured according to Test Example 2. The results are shown in Figures 4 and 5, respectively. show.

[0093] The amount of related substances was measured according to Test Example 4. The results are shown in Table 5.

[0094] As is clear from the results of Figures 4 and 5, the amount of the active ingredient (bilastine) was 6 to 22% by mass. Within this range, the formulation has both high hardness and rapid disintegration, and when humidified (40℃ / 75%RH It was confirmed that the tablet retained sufficient hardness and rapid disintegration even after 1 day of storage. As is clear from the results in Table 5, no significant increase in the amount of related substances due to moisture absorption was observed. It was confirmed that the composition has good storage stability.

[0095] [Table 5]

Claims

1. (1) 2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-yl]piperidin-1-yl}ethyl)phenyl]-2-methylpropanoic acid or a salt thereof, (2) A granule consisting of D-mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol (completely saponified), and (3) Crospovidone An orally disintegrating tablet comprising:

2. The total amount of the orally disintegrating tablet is 100.0% by mass. (1) The orally disintegrating tablet according to claim 1, containing 5.0 to 23.0% by mass of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-yl]piperidin-1-yl}ethyl)phenyl]-2-methylpropanoic acid or a salt thereof.

3. The total amount of the orally disintegrating tablet is 100.0% by mass. (3) The orally disintegrating tablet according to claim 1 or 2, containing 1.0 to 10.0% by mass of crospovidone.

4. The total amount of the orally disintegrating tablet is 100.0% by mass. (3) The orally disintegrating tablet according to any one of claims 1 to 3, containing 1.0 to 5.0% by mass of crospovidone.

5. The total amount of the orally disintegrating tablet is 100.0% by mass. (3) The orally disintegrating tablet according to any one of claims 1 to 4, containing 3.0% by mass of crospovidone.

6. The total amount of the orally disintegrating tablet is 100.0% by mass. (2) The orally disintegrating tablet according to any one of claims 1 to 5, comprising 72.0 to 88.0% by mass of a granule containing 90.0 to 95.0% by mass of D-mannitol, 5.0 to 7.0% by mass of low-substituted hydroxypropyl cellulose, and 0.10 to 0.30% by mass of polyvinyl alcohol (completely saponified product).

7. The total amount of the orally disintegrating tablet is 100.0% by mass. (2) The orally disintegrating tablet according to any one of claims 1 to 6, comprising 64.0 to 84.0% by mass of D-mannitol, 3.0 to 6.2% by mass of low-substituted hydroxypropyl cellulose, and 0.07 to 0.30% by mass of polyvinyl alcohol (completely saponified).

8. The orally disintegrating tablet according to any one of claims 1 to 7, having a tablet hardness of 60 N or more.

9. The orally disintegrating tablet according to any one of claims 1 to 8, having a disintegration time of 30 seconds or less.

10. The orally disintegrating tablet according to any one of claims 1 to 9, having a disintegration time of 25 seconds or less.

11. (1) 2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-yl]piperidin-1-yl}ethyl)phenyl]-2-methylpropanoic acid or a salt thereof, (2) A granule consisting of D-mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol (completely saponified), and (3) Crospovidone A method for producing an orally disintegrating tablet comprising the steps of: mixing the components (1) to (3); and compressing the mixture into tablets.

12. (1) 2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-yl]piperidin-1-yl}ethyl)phenyl]-2-methylpropanoic acid or a salt thereof, (2) A granule consisting of D-mannitol, low-substituted hydroxypropyl cellulose and polyvinyl alcohol (completely saponified), and (3) Crospovidone A pharmaceutical composition which is an orally disintegrating tablet comprising:

13. 13. A pharmaceutical composition according to claim 12 for the treatment of an allergic disease or its symptoms.

Citation Information

Patent Citations

  • Bilastine orally disintegrating tablet and preparing method thereof

    CN104398481A

  • Bilastine-containing pharmaceutical composition and preparing method thereof

    CN104398512A

  • New benzimidazole derivative having antihistaminic activity

    JP1998059961A

  • Polymorph of 4-[2-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl]ethyl]-α,α-dimethylbenzenoacetic acid

    JP2005529120A

  • Composite granulated material and immediate release tablet and production method thereof

    JP2015117240A